

“Potential safety concern” halts clinical trial of Eli Lilly antibody treatment



Pharmaceutical giant Eli Lilly has suspended clinical trials of its monoclonal antibody drug.
(Photo: Internet)

Indianapolis, October 14 (RHC)-- Pharmaceutical giant Eli Lilly has suspended clinical trials of its monoclonal antibody drug over an unspecified "potential safety concern."

President Donald Trump touted a similar drug produced by Regeneron as a "cure" for COVID-19 after he received a dose while hospitalized at Walter Reed Medical Center earlier this month.

Both Eli Lilly and Regeneron have applied for emergency use authorizations of their antibody therapies.

<https://www.radiohc.cu/en/noticias/internacionales/236778-potential-safety-concern-halts-clinical-trial-of-eli-lilly-antibody-treatment>



Radio Habana Cuba